uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
15.55
-1.39 (-8.21%)
Mar 13, 2026, 3:52 PM EDT - Market open
uniQure Revenue
In the year 2025, uniQure had annual revenue of $16.10M, down -40.64%. uniQure had revenue of $5.57M in the quarter ending December 31, 2025, with 6.65% growth.
Revenue (ttm)
$16.10M
Revenue Growth
-40.64%
P/S Ratio
61.06
Revenue / Employee
$72,842
Employees
221
Market Cap
972.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.10M | -11.02M | -40.64% |
| Dec 31, 2024 | 27.12M | 11.28M | 71.17% |
| Dec 31, 2023 | 15.84M | -90.64M | -85.12% |
| Dec 31, 2022 | 106.48M | -417.52M | -79.68% |
| Dec 31, 2021 | 524.00M | 516.72M | 7,096.84% |
| Dec 31, 2019 | 7.28M | -5.83M | -44.45% |
| Dec 31, 2017 | 13.11M | -11.99M | -47.78% |
| Dec 31, 2016 | 25.10M | 21.05M | 520.14% |
| Dec 31, 2013 | 4.05M | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 376.13M |
| Geron | 183.88M |
| AbCellera Biologics | 75.13M |
| EyePoint | 31.37M |
| Inventiva | 19.93M |
| Precigen | 6.31M |
| Aktis Oncology | 5.56M |
| DBV Technologies | 5.50M |
QURE News
- 4 days ago - This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down - Market Watch
- 7 days ago - Federal health officials attacked an Amsterdam-based biotech company seeking approval of a Huntington's disease treatment and accused it of lying - WSJ
- 8 days ago - FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease - CNBC
- 8 days ago - Sr. FDA official calls Uniqure's Huntington's disease treatment a failure - Reuters
- 8 days ago - FDA Defends Call For Placebo Study In uniQure Huntington's Gene Therapy Trial - Benzinga
- 8 days ago - FDA official says UniQure fell short on Huntington's trial, defends new study request - Reuters
- 10 days ago - These Analysts Cut Their Forecasts On uniQure Following Q4 Results - Benzinga
- 10 days ago - uniQure: The Worst Case Scenario Just Got Official (Rating Downgrade) - Seeking Alpha